Biology subjects

Hollas, M. A. R.

Publications and source records attributed to Hollas, M. A. R..

4 recordsLinked to original sources

bioRxiv2026

Deep Proteoform Sequencing with Top-Down Direct Mass Technology

Individual Ion Mass Spectrometry (I2MS) using Direct Mass Technology mode on an Orbitrap mass spectrometer (DMTm) increases sensitivity, resolution, and mass range for protein analysis. Here, we present an end-to-end workflow for deep proteoform sequencing using top-down mass spectrometry with DMTm. By assigning the charge of individual fragment ions and converting spectra from the m/z to the mass domain, DMTm resolves overlapping isotopic distributions that have limited conventional top-down mass spectrometry. Across different fragmentation modes on Orbitrap mass spectrometers, top-down DMTm significantly outperformed conventional top-down mass spectrometry methods. For a glycosylated 50.8 kDa antibody heavy chain, sequence coverage was greatly increased, from 27.5% to 83.3%, in 10 minutes of acquisition using a single fragmentation mode. Coverage of the middle 350 residues improved from 0% to >95%, demonstrating near-complete coverage of the difficult-to-characterize internal region of a large protein. The fragmentation patterns of DMTm were found to be complementary to conventional top-down, with higher internal coverage for DMTm and higher terminal coverage for conventional. Accordingly, aggregation of the data from the two modes further increased heavy chain sequence coverage to 90.2%. A new software platform, Proteoform Studio, provided optimized ion processing for improved sequence coverage and enabled real-time experimental monitoring as individual ions were accumulated. The platform automatically integrates conventional and DMTm data to provide the most comprehensive sequence coverage possible. Together, these advances enable substantially deeper proteoform sequencing and establish a straightforward, complete top-down DMTm workflow to confidently define proteoforms in biological systems and biotherapeutic development.

bioinformatics↗

bioRxiv2026

Targeted Analysis of >1500 Plasma Proteoforms via Individual Ion Mass Spectrometry

Plasma proteomics has long sought to accessibly sense human biology, precisely detect disease states, and advance diagnostics through clinical translation. In recent years, companies with defined panels such as Olink and Somascan have entered the field to complement bottom-up mass spectrometry (BUP). This study leverages a novel mass spectrometry platform to capture targeted proteoform information lost by mainline antibody-, aptamer-, and BUP-driven workflows. The Plasma Proteoform Assay (PPA) uses Individual Ion Mass Spectrometry (I{superscript 2}MS) to resolve mixtures of intact proteins presented by direct injection. Two proteoform panels, PPA 526 and PPA 1514, were defined from human plasma samples obtained from 81 individuals. The panels quantify 526 proteoforms derived from 59 genes and 1,514 proteoforms from 155 genes, respectively. Reproducibility for both panels showed coefficients of variation below 20% for most proteoforms (59-80%). PPA was benchmarked in studies including subjects with hepatic cirrhosis (N=30) and resilient agers carrying a SERPINE1 (PAI 1) mutation (N=27). PPA signatures distinguished SERPINE1 mutation carriers from affected individuals and provided sufficient resolution to discriminate among cirrhosis disease stages. In summary, we present PPA 526 and PPA 1514, the first scalable plasma proteoform panels capable of tracking hundreds to thousands of targets in a few minutes per sample.

biochemistry↗

bioRxiv2024

Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression

Cirrhosis, advanced liver disease, affects 2-5 million Americans. While most patients have compensated cirrhosis and may be fairly asymptomatic, many decompensate and experience life-threatening complications such as gastrointestinal bleeding, confusion (hepatic encephalopathy), and ascites, reducing life expectancy from 12 to less than 2 years. Among patients with compensated cirrhosis, identifying patients at high risk of decompensation is critical to optimize care and reduce morbidity and mortality. Therefore, it is important to preferentially direct them towards specialty care which cannot be provided to all patients with cirrhosis. We used discovery Top-down Proteomics (TDP) to identify differentially expressed proteoforms (DEPs) in the plasma of patients with progressive stages of liver cirrhosis with the ultimate goal to identify candidate biomarkers of disease progression. In this pilot study, we identified 209 DEPs across three stages of cirrhosis (compensated, compensated with portal hypertension, and decompensated), of which 115 derived from proteins enriched in the liver at a transcriptional level and discriminated the three stages of cirrhosis. Enrichment analyses demonstrated DEPs are involved in several metabolic and immunological processes known to be impacted by cirrhosis progression. We have preliminarily defined the plasma proteoform signatures of cirrhosis patients, setting the stage for ongoing discovery and validation of biomarkers for early diagnosis, risk stratification, and disease monitoring. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=156 SRC="FIGDIR/small/599662v1_ufig1.gif" ALT="Figure 1"> View larger version (41K): org.highwire.dtl.DTLVardef@797e27org.highwire.dtl.DTLVardef@495bb7org.highwire.dtl.DTLVardef@2478a9org.highwire.dtl.DTLVardef@6dbc0a_HPS_FORMAT_FIGEXP M_FIG C_FIG HighlightsO_LIPerformed a pilot top-down LC-MS/MS analysis to identify proteoforms (PFRs) in the plasma of patients with 3 progressive stages of liver cirrhosis. C_LIO_LIIdentified 2867 proteoforms (PFRs) and 209 differentially regulated proteoforms (DRPs) in the different stages of the disease. C_LIO_LIIdentified DRP profiles able to potentially distinguish early from late stages of the disease, including 115 liver-derived DRPs. C_LIO_LIFibrinogen alpha chain, haptoglobin, and Apo A-I are the proteins with the highest number of DRPs and represent potential candidate biomarkers of liver cirrhosis progression. C_LI

molecular biology↗

bioRxiv2021

Direct Imaging and Identification of Proteoforms up to 70 kDa from Human Tissue

Imaging of proteoforms in human tissues is hindered by low molecular specificity and limited proteome coverage. Here, we introduce proteoform imaging mass spectrometry (PiMS), which increases the size limit for proteoform detection and identification by 4-fold compared to reported methods, and reveals tissue localization of proteoforms at <80 m spatial resolution. PiMS advances proteoform imaging by combining ambient nanospray desorption electrospray ionization (nano-DESI) with ion detection using individual ion mass spectrometry (I2MS). We demonstrate the first proteoform imaging of human kidney, identifying 169 of 400 proteoforms <70 kDa using top-down mass spectrometry and database lookup from the human proteoform atlas, including dozens of key enzymes in primary metabolism. PiMS images reveal distinct spatial localizations of proteoforms to both anatomical structures and cellular neighborhoods in the vasculature, medulla, and cortex regions of the human kidney. The benefits of PiMS are poised to increase proteome coverage for label-free protein imaging of tissues. TeaserNano-DESI combined with individual ion mass spectrometry generates images of proteoforms up to 70 kDa.

biochemistry↗